IDO1 and type 1 diabetes mellitus: A previous study showed that the DCs vaccine used to inhibit type 1 diabetes activated IDO1 expression in vivo by stimulating the nonclassical NF-κB pathway, which led to the suppression of DC-mediated type 1 diabetes autoimmunity (51).